Deoxycorticosterone Acetate-salt Rats Research Articles

Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats

Angiotensin II and nitric oxide (NO) may play a role in hypertensive cardiovascular remodeling. We evaluated the effects of long-term treatment with quinapril, an angiotensin converting enzyme (ACE) inhibitor, on expression of endothelial NO synthase (eNOS), ACE, and angiotensin II type 1 (AT1) receptor in the left ventricle and evaluated these relations to myocardial remodeling in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Deoxycorticosterone acetate-salt rats were induced with weekly injections of DOCA (30 mg/kg) and 1% saline in drinking water after right nephrectomy. Quinapril (DOCA-QUI, 10 mg/kg/day, subdepressor dose) or AT1 receptor antagonist TCV-116 (DOCA-TCV, 5 mg/kg/day, subdepressor dose) or vehicle (DOCA-V) were given after induction of DOCA-salt hypertension for 5 weeks, and age-matched sham-operated rats (ShC) served as a control group. The eNOS expression in the left ventricle were significantly decreased in DOCA-V compared with ShC, and were significantly increased in DOCA-QUI and DOCA-TCV compared with ShC and DOCA-V. The gene expression of ACE, AT1 receptor, and type I collagen mRNA were significantly increased in DOCA-V compared with ShC, and significantly suppressed in DOCA-QUI compared with DOCA-V. The DOCA-V rats demonstrated a significant increase of the wall-to-lumen ratio, perivascular fibrosis, and myocardial fibrosis, with all these parameters being significantly improved by quinapril. Myocardial remodeling in DOCA-salt hypertensive rats was significantly ameliorated by a subdepressor dose of quinapril, which may be due to an increase in eNOS mRNA and protein expression and a decrease in ACE and AT1 receptor mRNA expression in the left ventricle.

Adenovirus-Mediated Human Kallikrein Gene Delivery Increases Endogenous Rat Tissue Kallikrein in Hypertensive Rat Models

P201 Our recent studies showed that adenovirus-mediated human tissue kallikrein gene delivery attenuated hypertension, cardiac hypertrophy, and renal injury in various hypertensive rat models. However, mechanisms underlying the beneficial effects of human kallikrein gene delivery are not clear. In the present study, we investigated the potential of human kallikrein gene delivery on synthesis and excretion of endogenous rat tissue kallikrein in normotensive and hypertensive rat models. Adenovirus carrying the human kallikrein cDNA under the control of cytomegalovirus (CMV) promoter/enhancer was administered via tail vein injection. Control rats received adenovirus harboring the b-galactosidase or luciferase gene under control of the CMV promoter/enhancer. A single injection of the human tissue kallikrein gene caused a prolonged blood pressure-lowering effect in spontaneously hypertensive rats, two kidney-one clip, Dahl salt-sensitive, deoxycorticosterone acetate-salt and monocrotaline-induced pulmonary hypertensive rats, while systolic blood pressure of normotensive Sprague-Dawley rats remained unaltered. Human kallikrein gene delivery significantly increased endogenous rat tissue kallikrein levels in the kidney and urine of different models of hypertensive rats as compared with their respective controls. However, urinary excretion of rat tissue kallikrein was not affected by human kallikrein gene delivery in normotensive rats. The endogenous rat tissue kallikrein mRNA expression in the kidney remained unaltered after human kallikrein gene delivery, which indicated that expression of human kallikrein in hypertensive rats increased endogenous rat kallikrein synthesis and excretion. These findings indicate that beneficial effects of human kallikrein gene delivery in hypertensive rat models are mediated, at least in part, by enhanced endogenous tissue kallikrein-kinin system.

Vasopressin V1a and V2 receptor mRNA in deoxycorticosterone acetate-salt hypertension in the rat.

1. Vasopressin V1a and V2 receptors are differentially regulated in deoxycorticosterone acetate-salt hypertension. This paper investigated whether the changes were due to transcription changes in receptor mRNA assessed by in situ hybridization histochemistry (liver V1a receptor) and by reverse transcription-polymerase chain reaction (kidney V1a and V2 receptor). 2. Systolic blood pressure and plasma vasopressin levels were significantly elevated in deoxycorticosterone acetate-salt rats (n = 24) compared with water-control (n = 28) and salt-control rats (n = 28) (P < 0.001). Plasma sodium was elevated in deoxycorticosterone acetate-salt rats compared with both control groups (P < 0.01) and plasma osmolality was elevated in deoxycorticosterone acetate-salt rats compared with water-control rats (P < 0.05). 3. Binding kinetic studies demonstrated downregulation of liver V1a and kidney V2 receptors in deoxycorticosterone acetate-salt rats compared with water-control and salt-control rats (P < 0.05). This was not associated with any change in liver V1a receptor mRNA (P = 0.95), or in kidney V1a (P = 0.79) or V2 receptor mRNA (P = 0.96). 4. In deoxycorticosterone acetate-salt hypertension, downregulation of liver V1a and kidney V2 receptors occurs in the setting of stable vasopressin gene transcription. These results suggest that changes in receptor processing may be responsible for the differential regulation of vasopressin receptors that occurs in deoxycorticosterone acetate-salt hypertension.

Tissue-Specific Regulation of Renal and Cardiac Atrial Natriuretic Factor Gene Expression in Deoxycorticosterone Acetate–Salt Rats

Atrial natriuretic factor (ANF) is expressed in several noncardiac tissues where it may have an autocrine or paracrine function. Such function may be expected of locally synthesized ANF in the renal parenchyma. Previous investigations of the existence of ANF mRNA in the renal parenchyma have yielded conflicting results. The investigations reported here were designed to detect and measure ANF mRNA in normal rats and in rats subjected to a deoxycorticosterone acetate (DOCA)-salt treatment schedule known to strongly activate cardiac ANF gene expression. The expression of the renal ANF gene was measured using a newly developed quantitative competitive reverse transcription-polymerase chain reaction (QC-RT-PCR). This method uses an internal competitor that serves as an internal standard and makes the procedure independent of measurement relative to housekeeping genes. It was found that renal ANF mRNA levels were 10(7) times lower than those found in left or right atria, but immunoreactive (ir) renal ANF concentration by specific radioimmunoassay was 10(4) times lower than that of atrial irANF levels. Reverse-phase high-performance liquid chromatography analysis revealed that more than 99% of renal irANF is processed ANF(99-126). This finding suggests that most of the irANF measured in kidney extracts likely originates from atrial sources. Left atrial ANF mRNA levels after 1 week of DOCA-salt treatment was significantly higher than that of control rats ([21.06+/-2.99] x 10(-l5) mol/microg total RNAversus [8.59 +/-1.26] x 10(-5) mol/microg total RNA, P<.05). However, renal ANF mRNA levels in DOCA-salt rats were significantly decreased compared with those of control rats ([1.64+/-0.34] x 10(-22) mol/microg total RNA versus [3.96+/-0.61]x 10(-22) mol/microg total RNA, P<.05). These results indicate that (1) renal ANF mRNA can be consistently and specifically demonstrated after reverse transcription and PCR amplification; (2) renal and cardiac ANF synthesis are regulated in a tissue-specific, opposite manner during DOCA-salt treatment; and (3) the finding that renal ANF mRNA is downregulated by DOCA-salt treatment together with previous findings suggest the need for further investigation into the role of renal ANF mRNA downregulation in the pathogenetic mechanism that leads to volume expansion and hypertension after chronic DOCA-salt treatment.

LACK OF INVOLVEMENT OF NITRIC OXIDE IN MEDIATING INCREASED MICROVASCULAR REACTIVITY IN DEOXYCORTICOSTERONE-ACETATE SALT HYPERTENSIVE RATS. • 312

Previous studies in our laboratory have demonstrated that arteriolar dilation mediated by stimulation of endogenous nitric oxide (NO) release, are depressed during the established stage of hypertension in the spontaneously hypertensive rat. In this study, the microvascular reactivity and the effects of NO blockade were examined in two groups of male Sprague-Dawley rats: normotensive control (NT) and deoxycorticosterone-acetate salt (DOCA) hypertensive. Hypertension was induced in the experimental group by twice a week subcutaneous injections of 30mg/kg of the DOCA-salt after uni-nephrectomy. The NT (BP=130±8; n=6) and DOCA (BP=168±1; n=6) groups were maintained on a normal and high sodium and potassium diet, respectively. Third order arterioles responses in the cremasteric muscle were then observed via in vivo closed circuit television microscopy at four weeks after induction of hypertension. Exposure of the microvasculature to acetylcholine or sodium nitroprusside did not reveal any significant differences in relaxation between arterioles of the NT and DOCA groups. In addition, NO blockade with Nw-nitro-L-arginine methyl ester (L-NAME) produced significant reductions in resting arteriolar diameters in both groups that were similar (41±13% and 48±10%, respectively). However, an increase in contractile sensitivity to norepinephrine was observed in the DOCA rats. These data indicate that basal and stimulated release of NO is not attenuated in the late stages of DOCA-salt hypertension. Thus, attenuation of NO release does not to appear to be responsible for the elevated microvascular reactivity associated with DOCA-salt hypertension.

Mechanisms for altered endothelium-dependent vasorelaxation in isolated kidneys from experimental hypertensive rats

To study mechanisms for attenuated endothelium-dependent vasorelaxation in hypertension, we examined the effects of acetylcholine (ACh) on renal vascular resistance (RVR) and release rates of endothelium-derived relaxing factor (EDRF) in kidneys isolated from spontaneously hypertensive rats (SHR), deoxycorticosterone acetate (DOCA) salt-hypertensive (DOCA salt) rats, and Dahl salt-sensitive (Dahl S) rats. Decreases in RVR by ACh were smaller in hypertensive rats than in their normotensive controls. The release rate of nitric oxide into the perfusate, which was estimated using nitrite-nitrate as an index, did not differ between SHR and Wistar-Kyoto rats (WKY). However, the release rate of EDRF was markedly decreased in both DOCA salt rats and Dahl S rats compared with their normotensive controls (10(-7) M ACh: DOCA salt 45 +/- 6 vs. control 410 +/- 60 pmol.min-1.g-1 kidney wt, P < 0.001). In SHR, high-K+ perfusion or pretreatment with glibenclamide, inhibitors of endothelium-derived hyperpolarizing factor (EDHF), significantly reduced ACh-induced vasorelaxation only in WKY, resulting in no differences in the RVR reduction between SHR and WKY. Thus attenuated ACh-induced vasorelaxation in the SHR kidney may be attributed to a decrease in EDHF, but to a decrease in EDRF in DOCA salt rats and Dahl S rats.

Polyamines, vascular smooth muscle, and deoxycorticosterone acetate-salt hypertension.

This study was performed to determine if an alteration in vascular polyamine contents is associated with the development of deoxycorticosterone acetate-salt hypertension. The effects of chronic administration of alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase and thus polyamine biosynthesis, on vascular polyamine contents, structure, and function as well as the development of hypertension was studied. Control and deoxycorticosterone acetate-salt rats received either tap water or a drinking solution containing alpha-difluoromethylornithine for 6 weeks, during which period systolic blood pressures were recorded. Vascular reactivity studies were performed on rings of aorta and tail artery. Medial thickness, vessel weight, and vascular polyamine contents were also assessed in these arteries. alpha-difluoromethylornithine treatment had no significant effect on either systolic blood pressure or vascular structure, function, and polyamine contents of control animals. The elevation in blood pressure and the increase in medial thickness, ring weight, and vascular polyamine contents as well as altered vascular reactivity observed in deoxycorticosterone acetate-salt rats was significantly attenuated by alpha-difluoromethylornithine treatment. These results are the first to demonstrate that vascular polyamine contents are elevated in the deoxycorticosterone acetate-salt rat and that chronic alpha-difluoromethylornithine treatment prevents the rise in vascular polyamines as well as the elevation in blood pressure and attendant changes in the vasculature. Thus, the increase in vascular polyamines may comprise a critical link between the initiating stimuli and the alterations in vascular structure and function implicated in the pathogenesis of deoxycorticosterone acetate-salt hypertension.

Nicotine impairs reflex renal nerve and respiratory activity in deoxycorticosterone acetate-salt rats.

Smoking exacerbates the increase in arterial pressure in hypertension. The effect of nicotine on the baroreceptor-mediated reflex responses of renal nerve activity (RNA), heart rate, and respiratory activity (minute diaphragmatic activity [MDA]) after bolus injections of phenylephrine was compared in deoxycorticosterone acetate (DOCA)-salt sensitive and normotensive rats. Osmotic minipumps that dispensed either nicotine (2.4 mg/kg/day) or saline were implanted in DOCA and normotensive rats for 18 days. Anesthetized DOCA-nicotine, DOCA-saline, control-nicotine, and control-saline rats had mean arterial pressures (MAP) of 117 +/- 3, 110 +/- 9, 90 +/- 3, and 89 +/- 5 mm Hg, respectively. Nicotine decreased the sensitivity (p less than 0.05) of baroreceptor reflex control of RNA (% delta RNA/delta MAP) in the DOCA-nicotine rats (-0.92 +/- 0.08) compared with the DOCA-saline (-1.44 +/- 0.16), control-nicotine (-1.45 +/- 0.08), or control-saline (-1.45 +/- 0.21) rats. The reflex decrease in respiratory activity (% delta MDA/delta MAP x 100) was impaired (p less than 0.01) in both control-nicotine (-24.5 +/- 3.3) and DOCA-nicotine (-18.2 +/- 4.6) rats compared with control-saline (-59.2 +/- 9.1) and DOCA-saline (-52.5 +/- 9.9) rats. The reflex decrease in heart rate (absolute delta HR/delta MAP) in both DOCA-nicotine (1.56 +/- 0.17) and control-nicotine (1.54 +/- 0.24) rats was augmented compared with DOCA-saline and control-saline rats (0.91 +/- 0.12 and 0.97 +/- 0.14).(ABSTRACT TRUNCATED AT 250 WORDS)

Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats

To assess the potential role of the lipoxygenase (LO) pathway in the vasculature in an angiotensin II (ANG II)-dependent model of hypertension, we investigated the effect of LO pathway inhibition on blood pressure in the two-kidney, one-clip (2K,1C) Goldblatt hypertensive rat. The development of renovascular hypertension in 2K,1C rats was attenuated by oral administration of phenidone (Phe, 60 mg.kg-1.day-1), a nonselective LO inhibitor, throughout the 3 wk of observation after renal artery constriction. In contrast, the same treatment protocol had no effect on the evolution of hypertension in the deoxycorticosterone acetate-salt rat, which is considered to be an ANG II-independent form of hypertension. The hypotensive effect of Phe was not associated with changes in plasma renin or aldosterone concentration (PRC and PAC, respectively). In vitro synthesis of 12-hydroxyeicosatetraenoic acid (12-HETE) by aortic segments was increased in 2K,1C hypertensive rats compared with sham-operated rats. In addition, the synthesis of 12-HETE was suppressed by the in vitro addition of Phe (10(-4) M) to aortic-segment incubates obtained from 2K,1C rats and sham-operated rats. Acute administration of Phe (30 or 60 mg/kg) in 2K,1C hypertensive rats produced a rapid and sustained decrease in mean blood pressure (MBP). This decrease in MBP was accompanied by a brisk rise in PRC and PAC. In contrast, bolus administration of indomethacin, a selective cyclooxygenase inhibitor, did not affect MBP, PRC, or PAC.(ABSTRACT TRUNCATED AT 250 WORDS)

Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.

The effects of SCH 34826, an orally active neutral metalloendopeptidase inhibitor, on responses to atrial natriuretic factor-(103-125) or -(99-126) and on blood pressure were evaluated in rats. SCH 34826 (10, 30, and 90 mg/kg s.c. and 90 mg/kg p.o.) potentiated the antihypertensive action of atrial natriuretic factor (30 micrograms/kg i.v.) in conscious spontaneously hypertensive rats. SCH 34826 (90 mg/kg) also potentiated the diuretic and natriuretic responses to atrial natriuretic factor (30 micrograms/kg i.v.) as well as the plasma levels achieved after peptide injection. SCH 34826 significantly reduced blood pressure in the conscious deoxycorticosterone acetate-salt hypertensive rat, at doses of 90 mg/kg s.c. (-35 +/- 12 mm Hg), 10 mg/kg p.o. (-30 +/- 7 mm Hg), and 90 mg/kg p.o. (-45 +/- 6 mm Hg). SCH 34826 was devoid of acute antihypertensive activity in the spontaneously hypertensive rat but reduced blood pressure by day 3 of a 5-day treatment schedule. SCH 34826 (90 mg/kg s.c.) enhanced urine volume output in the deoxycorticosterone acetate-salt rat (2.78 +/- 0.6 vs. 1.27 +/- 0.3 ml/100 g/3 hr in vehicle-control rats, p less than 0.05). SCH 34826 (90 mg/kg s.c.) increased plasma levels of atrial natriuretic factor at 1 hour (753 +/- 89 vs. 451 +/- 79 pg/ml in vehicle-treated rats, p less than 0.05) but not 3 hours after dosing. The renal excretion of atrial natriuretic factor (3,092 +/- 1,089 vs. 21 +/- 6 pg/100 g/3 hr in vehicle-treated rats, p less than 0.05) and cyclic guanosine monophosphate (2,131 +/- 509 vs. 879 +/- 168 pg/100 g/3 hr in vehicle-treated rats, p less than 0.05) was markedly elevated by SCH 34826 in deoxycorticosterone acetate-salt rats. These studies suggest that neutral endopeptidase inhibition may represent a new approach to treatment of some forms of hypertension.

Dietary Potassium, Blood Pressure and Peripheral Adrenergic Responsiveness in the Deoxycorticosterone Acetate-Salt Rat

This study investigated the effect of 6 weeks of dietary potassium (K) supplementation on blood pressure and in vivo and in vitro peripheral adrenergic responsiveness in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Dietary K supplementation did not affect the development of hypertension in DOCA-salt rats. The chronotropic and dipsogenic responses to isoproterenol (ISO) administration were significantly decreased in DOCA-salt rats. Addition of K to the diet resulted in a complete normalization of both of these responses so that they were similar to controls. Aortic smooth muscle from DOCA-salt rats exhibited a significant reduction in the relaxation response to ISO. Dietary K supplementation resulted in only a partial normalization of this response. Enhanced norepinephrine responsiveness was observed in aortic smooth muscle from DOCA-salt rats, but was not affected by dietary K supplementation. These results show that: 1) a 0.5% dietary K supplementation in DOCA-salt rats does not prevent the development of hypertension, 2) the decreased peripheral beta-adrenergic responsiveness observed in DOCA-salt rats is partially normalized by the addition of K to the diet, and 3) the increased alpha- adrenergic sensitivity is not affected by the 0.5% dietary K supplementation in the DOCA-salt rat. It is concluded that dietary K supplementation has differential effects on peripheral alpha- and beta- adrenergic responsiveness in the DOCA-salt rat. These actions may be related to the lack of an antihypertensive effect of K in the present study.

Sodium pump activity and calcium relaxation in vascular smooth muscle of deoxycorticosterone acetate-salt rats.

The Na+-K+ pump activity was determined in femoral arterial smooth muscle from deoxycorticosterone acetate (DOCA)-salt hypertensive rats using potassium relaxation and ouabain-sensitive 86Rb uptake as indices. The membrane-stabilizing effect of calcium and its relation to Na+-K+ pump activity also were examined. Femoral arteries from DOCA-salt rats exhibited a greater relaxation in response to potassium addition after contraction with norepinephrine in a low potassium (0.6 mM) Krebs solution. The concentration of potassium required to produce a 50% relaxation was significantly less in DOCA-salt rats. Ouabain-sensitive 86Rb uptake was significantly greater at 3, 10, and 20 minutes of 86Rb incubation in femoral arteries from DOCA-salt rats. Linear regression analysis revealed a significant correlation between the uptake of 86Rb and time of incubation in both control and DOCA-salt rats. A significant difference in the slopes of the regression lines showed that the rate of uptake was greater in DOCA-salt rats. No difference was observed in ouabain-insensitive 86Rb uptake. A dose-dependent relaxation in response to increasing concentrations of calcium following contraction to norepinephrine was observed in femoral arteries from control and DOCA-salt rats. The relaxation was directly dependent on the level of extracellular potassium and was blocked by ouabain. Femoral arteries from DOCA-salt rats relaxed to a significantly greater extent in response to calcium at each level of potassium when compared with controls. These results provide further evidence for an increase in Na+-K+ pump activity in vascular smooth muscle from DOCA-salt hypertensive rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Extracellular calcium and altered vascular responsiveness in the deoxycorticosterone acetate-salt rat.

This study investigated the effects of altered extracellular Ca2+ on in vitro femoral arterial smooth muscle responsiveness in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Compared with controls, femoral arteries from DOCA-salt rats showed a significant increase in sensitivity to KCl and norepinephrine in normal Ca2+ (2.5 mM). Although no difference in maximal contractile response to KCl was observed between groups, there was a significant difference in maximal response to norepinephrine. Dose-response curves in low Ca2+ (0.25 mM) resulted in a significant decrease in the sensitivity of femoral arteries from DOCA-salt rats to KCl and NE so that the responses were similar to those of controls. Relaxation of femoral arteries from DOCA-salt rats after washout of the KCl contraction was significantly slower than that of controls in both low and normal Ca2+. Isoproterenol-induced relaxation of femoral arteries from DOCA-salt rats was significantly attenuated in normal Ca2+. Sensitivity of femoral arteries from DOCA-salt rats to isoproterenol increased in low Ca2+, but maximal relaxation was unaltered. Whereas no difference in maximal relaxation to NaNO2 was seen in femoral arteries from either group in normal Ca2+, a significant decrease in sensitivity to NaNO2 was observed in femoral arteries from DOCA-salt rats. In low Ca2+ the response of femoral arteries from DOCA-salt rats to NaNO2 was similar to that of controls. These results suggest that the increased vascular smooth muscle responsiveness to KCl and norepinephrine seen in DOCA-salt hypertension is due to increased sensitivity of the vascular smooth muscle to Ca2+. Extracellular Ca2+, however, plays only a minor role in the decreased vasodilator responsiveness seen in this form of hypertension.

Reduced renal vascular response to nerve stimulation and norepinephrine in DOCA–salt hypertensive rats

Vascular responses to nerve stimulation and norepinephrine (NE) administration were studied in kidneys perfused in situ at constant flow in uninephrectomized Sprague–Dawley rats made hypertensive by 5–6 weeks of deoxycorticosterone acetate (DOCA) – salt treatment. One- and two-kidney normotensive rats were used as controls. Renal blood flow on a weight basis did not differ significantly between the two control groups. Kidneys of DOCA–salt rats were nearly twice the size of those in one-kidney controls, but blood flow was only half that of controls when perfusion pressure was set at 100 mmHg (1 mmHg = 133.322 Pa). There were no differences in renal vascular responses to nerve stimulation (2–8 Hz) or NE (10–50 ng, ia) between the two control groups; however, in the DOCA–salt rats, responses to nerve stimulation were decreased by 71–87%, while those to NE were decreased by 35–40%. Similar reductions in the response to barium chloride were seen. NE concentration in the perfused kidneys averaged 183 ± 11, 104 ± 16, and 37 ± 3 ng/g in the two-kidney, one-kidney, and DOCA–salt groups, respectively. The decrease in NE concentration in DOCA–salt kidneys was greater than could be accounted for by changes in renal mass alone. In another group of uninephrectomized rats, renal vascular resistance was increased to levels seen in DOCA–salt kidneys by iv infusion of NE. Under these conditions, responses to bolus injections of NE (50 ng) were decreased by 38%. Taken together, the results suggest that renal vascular responses to nerve stimulation in DOCA–salt kidneys are markedly reduced because of (i) a reduced amount of NE available for release, and (ii) a decreased responsiveness of the renal vasculature to NE. The latter response, which may extend to other vasoconstrictors as well, is opposite to what has been shown frequently in isolated, perfused kidneys, and may be explained by the presence of elevated renal vascular tone in DOCA–salt kidneys perfused in situ.